US › Healthcare

Agios Pharm (AGIO)

US · Healthcare · Biotechnology

$31.60+3.47%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$44.7M
Revenue YoY
+259.3%
Net profit
$-100.7M
Profit YoY
+10.1%
EPS
$-1.69
EPS estimate
$-1.86
Net margin
-225.1%

EPS came in at -1.69 against a street estimate of -1.86 — a beat of 9.1%.

Key statistics

Market cap
$1.79B
Forward P/E
2.5
P/B
1.75
Book value
$20.41
EPS (TTM)
$-7.01
52-week high
$46.00
52-week low
$22.24
50-day MA
$34.19
200-day MA
$31.63
Beta
0.54

Analyst view

Analysts rate Agios Pharm a buy (6 buy, 3 hold, 0 sell out of 9) with an average price target of $45.38.

Shareholding

Insiders
1.12%
Institutions
107.90%

Largest institutional holders

FundStake
BlackRock Inc9.64%
Farallon Capital Management, L.L.C.9.52%
State Street Corp5.64%
Armistice Capital, LLC4.55%
Erste Asset Management GmbH4.53%
D. E. Shaw & Co LP4.49%
Vanguard Capital Management, LLC4.41%
Lynx1 Capital Management, LP4.37%

Recent filings & reports

DocumentDate
Quarterly report · Q2 20262026-07-30
Results announced · Q3 20262026-07-30
Board / officer change · Q2 20262026-06-18
Quarterly report · Q1 20262026-04-29
Results announced · Q2 20262026-04-29
Proxy statement · Q2 20262026-04-24
Annual report FY20252026-02-12
Results announced · Q1 20262026-02-12

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Agios Pharm — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.